SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market participants are weighing geopolitical tensions and rising bond yields against high-profile trade optimism following summit meetings in Beijing. Community discussion is heavily divided, with some traders anticipating a technical correction or 'V-shaped' recovery, while others express caution over stretched equity valuations and potential volatility surrounding monthly options expiration.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending due to renewed optimism regarding chip sales in China, fueling investor anticipation as the company nears its upcoming earnings report. The community remains deeply divided, with bulls pointing to the stock's dominant AI market position and potential for continued growth, while bears express concerns over its massive market capitalization and the sustainability of current AI-driven valuations.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending following a strong quarterly earnings report featuring revenue growth that beat analyst expectations and raised full-year guidance, fueled by accelerating enterprise adoption of its AI-powered features. Community sentiment is heavily focused on a potential short squeeze, with investors highlighting significant short interest and arguing that the companys strong net dollar retention and essential role in design workflows prove its long-term value despite broader market concerns about AI competition.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure and volatility as investors weigh the impact of an ongoing OpenAI-related legal battle against the company's broader AI integration and cloud infrastructure strategy. While community sentiment remains divided between those viewing the current price weakness as a long-term accumulation opportunity and those frustrated by its relative underperformance compared to other mega-cap tech, active discussions highlight a rotation toward software monetization and potential catalysts from upcoming legal proceedings.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Market participants are actively debating the sustainability of current highs, with intense focus on the AI sector's massive capital expenditure and the broader implications of rising bond yields. Community discussion is dominated by a divide between those betting on continued momentum driven by corporate earnings and those positioning for potential volatility around options expiration.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest ahead of a highly anticipated plenary presentation at the AUA annual meeting, where the company will share updated, extended follow-up data from its pivotal Phase 3 trial. The community is actively discussing the potential for this data to solidify the drug's role as a practice-changing standard of care, with sentiment bolstered by strong institutional backing and speculation regarding the asset's commercial value in the large localized prostate cancer market.

Robo.ai, Inc. engages in the design and development of smart electric vehicles. It aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology. The company was founded in 2016 and is headquartered in Dubai, United Arab Emirates.

Robo.ai Inc. - Ordinary Shares - Class B

Robo.ai Inc.

Robo.ai Inc. ($AIIO) is trending as retail traders leverage extreme short interest and high borrow rates to fuel intense volatility and speculative price action. While some community members are highlighting the stock's recent multi-day rally and potential for a short squeeze, others remain cautious of the rapid swings and high-risk nature of these parabolic moves in low-float stocks.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors in SOXS are navigating high market volatility as traders react to major geopolitical tensions involving Iran and trade negotiations with China, while balancing concerns over persistent inflation data. The community remains deeply divided, with some betting on a massive semiconductor bubble burst while others caution against the significant risks and daily decay associated with holding leveraged instruments during this tech-heavy market rally.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is rallying following a $100 million strategic investment from the Winklevoss Capital Fund, paired with better-than-expected quarterly results. The community is actively discussing potential for a short squeeze given high short interest, while some remain cautious due to ongoing legal scrutiny and the stock's significant decline since its IPO.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending amid extreme volatility as investors react to sharp reversals in semiconductor sector momentum, fueling heated debate between bulls looking to buy the dip and bears arguing the recent parabolic surge has entered a major blow-off top. The conversation is heavily focused on the dangers of daily leverage decay and conflicting signals from high-profile market participants regarding the sustainability of the ongoing AI-driven rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook

(RTTNews) - Royalty Pharma plc (RPRX) on Thursday reported higher first-quarter earnings, supported mainly by growth in income from financial royalty assets...

Royalty Pharma Q1 Earnings Call Highlights

Royalty Pharma (NASDAQ:RPRX) reported what executives described as a "strong start" to 2026, driven by double-digit growth in cash receipts, active capital deployment and a series of clinical and regulatory developments across its portfolio, according to management's remarks on the company's first-q...

RPRX vs. AMGN: Which Stock Is the Better Value Option?

Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?

Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +6.56% and +3.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week High  - Still a Buy?

Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year High - Here's What Happened...

Charles River Gears Up for Q1 Earnings: What's in the Cards?

CRL heads into Q1 earnings results with declining EPS estimates, mixed segment trends and Manufacturing Solutions strength offsetting softness in RMS and DSA.

PFA Pension Forsikringsaktieselskab Acquires New Holdings in Royalty Pharma PLC $RPRX

PFA Pension Forsikringsaktieselskab purchased a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with...

Pictet Asset Management Holding SA Sells 62,539 Shares of Royalty Pharma PLC $RPRX

Pictet Asset Management Holding SA cut its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 16.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 313,510 shares of...

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

RPRX
Royalty Pharma plc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest RPRX News

RPRXRoyalty Pharma plc - Ordinary Shares - Class A